share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A：其他
美股SEC公告 ·  11/13 16:40

Moomoo AI 已提取核心信息

Transcode Therapeutics, Inc. has issued an open letter to shareholders dated November 12, 2024, regarding a Special Meeting scheduled for November 22. The meeting's agenda includes a proposal for shareholders to authorize the Board of Directors to effect a reverse stock split if deemed necessary. The company's management and directors are seeking this authorization as a contingency plan to maintain their Nasdaq listing, which is contingent on the company's stock closing at $1.00 per share or more for any ten-day period before December 31, 2024. Failure to meet this requirement could result in Nasdaq delisting, which the company believes would materially affect its value and its ability to raise capital. The need to raise additional capital is urgent for the continuation of clinical trials and other operations. The management and directors of Transcode Therapeutics are unanimously in favor of maintaining the Nasdaq listing and are hopeful that the reverse split will not be necessary.
Transcode Therapeutics, Inc. has issued an open letter to shareholders dated November 12, 2024, regarding a Special Meeting scheduled for November 22. The meeting's agenda includes a proposal for shareholders to authorize the Board of Directors to effect a reverse stock split if deemed necessary. The company's management and directors are seeking this authorization as a contingency plan to maintain their Nasdaq listing, which is contingent on the company's stock closing at $1.00 per share or more for any ten-day period before December 31, 2024. Failure to meet this requirement could result in Nasdaq delisting, which the company believes would materially affect its value and its ability to raise capital. The need to raise additional capital is urgent for the continuation of clinical trials and other operations. The management and directors of Transcode Therapeutics are unanimously in favor of maintaining the Nasdaq listing and are hopeful that the reverse split will not be necessary.
Transcode Therapeutics, Inc. 发布了一封致股东的公开信，日期为2024年11月12日，内容涉及定于11月22日举行的特别会议。会议议程包括向股东提议授权董事会在必要时实施反向拆股。公司的管理层和董事寻求这一授权，作为维持其纳斯达克上市的应急计划，该上市条件是公司股票在2024年12月31日前的任何十天内收盘价达到每股1.00美元或以上。如未能满足该要求，可能会导致纳斯达克退市，公司认为这将对其价值和融资能力产生重大影响。为了继续进行临床试验和其他运营，迫切需要筹集额外资金。Transcode Therapeutics 的管理层和董事们一致支持维持纳斯达克上市，并希望反向拆股不是必要的。
Transcode Therapeutics, Inc. 发布了一封致股东的公开信，日期为2024年11月12日，内容涉及定于11月22日举行的特别会议。会议议程包括向股东提议授权董事会在必要时实施反向拆股。公司的管理层和董事寻求这一授权，作为维持其纳斯达克上市的应急计划，该上市条件是公司股票在2024年12月31日前的任何十天内收盘价达到每股1.00美元或以上。如未能满足该要求，可能会导致纳斯达克退市，公司认为这将对其价值和融资能力产生重大影响。为了继续进行临床试验和其他运营，迫切需要筹集额外资金。Transcode Therapeutics 的管理层和董事们一致支持维持纳斯达克上市，并希望反向拆股不是必要的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间